Artículos por temáticas

Hyperkinetic movement disorders: Expanding the phenotype of congenital disorders of glycosylation.

Pandey S, Chouksey A.

Eur J Neurol. 2019 Jun 17. doi: 10.1111/ene.14013. [Epub ahead of print]

Paraneoplastic movement disorders: phenomenology, diagnosis, and treatment.

Chirra M, Marsili L, Gallerini S, Keeling EG, Marconi R, Colosimo C.

Eur J Intern Med. 2019 Jun 12. pii: S0953-6205(19)30183-9. doi: 10.1016/j.ejim.2019.05.023. [Epub ahead of print] Review.

Paroxysmal Movement Disorders: Recent Advances.

Xu Z, Lim CK, Tan LCS, Tan EK.

Curr Neurol Neurosci Rep. 2019 Jun 11;19(7):48. doi: 10.1007/s11910-019-0958-3. Review.

Telepsychiatry for patients with movement disorders: a feasibility and patient satisfaction study.

Seritan AL, Heiry M, Iosif AM, Dodge M, Ostrem JL.

J Clin Mov Disord. 2019 Jun 6;6:1. doi: 10.1186/s40734-019-0077-y. eCollection 2019.

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Pol

Lancet Neurol. 2019 Jun 19. pii: S1474-4422(19)30140-1. doi: 10.1016/S1474-4422(19)30140-1. [Epub ahead of print]

The role of Optical Coherence Tomography in Parkinsonism: A critical review.

Mailankody P, Lenka A, Pal PK.

J Neurol Sci. 2019 Jun 12;403:67-74. doi: 10.1016/j.jns.2019.06.009. [Epub ahead of print] Review.

Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone.

Rodrigues LD, Oliveira LF, Shinoda L, Scorza CA, Faber J, Ferraz HB, Britto LRG, Scorza FA.

Sci Rep. 2019 Jun 20;9(1):8965. doi: 10.1038/s41598-019-45518-z.

Association Between Drug Exposure and Occurrence of Parkinsonism in Korea: A Population-Based Case-Control Study.

Kim S, Cheon SM, Suh HS.

Ann Pharmacother. 2019 Jun 19:1060028019859543. doi: 10.1177/1060028019859543. [Epub ahead of print]

Changing views of the pathophysiology of Parkinsonism.

Wichmann T.

Mov Disord. 2019 Jun 19. doi: 10.1002/mds.27741. [Epub ahead of print] Review.

Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation

Lee EJ, Oh JS, Moon H, Kim MJ, Kim MS, Chung SJ, Kim JS, Jeon SR.

Neurosurgery. 2020 Apr 1;86(4):492-499. doi: 10.1093/neuros/nyz206.

Chronic Insomnia in Patients With Parkinson Disease: Which Associated Factors Are Relevant?

Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, de Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL.

J Geriatr Psychiatry Neurol. 2020 Jan;33(1):22-27. doi: 10.1177/0891988719856687. Epub 2019 Jun 18.

Decreased Striatal Vesicular Monoamine Transporter Type 2 Correlates With the Nonmotor Symptoms in Parkinson Disease.

Shi X, Zhang Y, Xu S, Kung HF, Qiao H, Jiang L, Zhu L, Guo Q, Yi C, Luo G, Wu L, Pei Z, Wang J, Zhang X, Chen L.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002664. [Epub ahead of print]

Updates and advances in the treatment of Parkinson disease.

Hayes MW, Fung VS, Kimber TE, O'Sullivan JD.

Med J Aust. 2019 Jun 16. doi: 10.5694/mja2.50224. [Epub ahead of print] Review.

Parkinsonism

Shrimanker I, Tadi P, Sánchez-Manso JC.

2021 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.

L-3-n-butylphthalide soft capsules in the treatment of Parkinson disease dementia: A systematic review and meta-analysis of randomized controlled trials.

Zhong R, Chen Q, Zhang X, Li M, Lin W.

Medicine (Baltimore). 2019 Jun;98(24):e16082. doi: 10.1097/MD.0000000000016082.